Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Gastroenterology. 2012 Aug 1;143(5):1308–1318. doi: 10.1053/j.gastro.2012.07.109

Fig. 7.

Fig. 7

A. Neutralization studies via ELISA show that pooledhIgG (active and not inactivated pooledhIgG) causes significant and concentration-dependent decrease (*; p<0.05) in the binding of SScIgG at the M3-RL2. B. Similar data were obtained when M3-RL2 was replaced with the membrane lysates. In these experiments, maximal OD is first observed following the incubation of 400 μg of HISMF with 5 μg/ml of SScIgGs. C. A working model suggests that SScIgGs lead to gastrointestinal motility dysfunction by blocking M3-R at the cholinergic neurotransmission at the neural and the SMC levels. Data further suggest that pooledhIgG neutralizes the SSc autoantibodies in the circulation thus attenuating these effects of SScIgGs on M3-R inhibition. This neutralization may in part reverse the pathophysiology of SSC gastrointestinal smooth muscle dysfunction.